No Detail Found!

A New Prognostic Index in Young Breast Cancer Patients

Author(s)
Hacer Demir Department of Medical Oncology, Afyon Health Sciences University School of Medicine,Afyonkarahisar,Turkey
Ayse Demirci Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Saliha Karagoz Eren Department of General Surgery, Kayseri City Hospital,Kayseri,Turkey
Ismail Beypinar Department of Medical Oncology, Eski_ehir City Hospital,Eski_ehir,Turkey
Sena Ece Davarc Department of General Surgery, Kayseri City Hospital,Kayseri,Turkey
Meltem Baykara Department of Medical Oncology, Afyon Health Sciences University School of Medicine,Afyonkarahisar,Turkey
Abstract
Objective:To evaluate the prognostic role of pan immune-in ammation value (PIV) in young breast cancer patients. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Afyon University of Health Sciences, School of Medicine Hospital, Turkey, between January 2010 and December 2020. Methodology: Patients who were under the age of 40 years at the time of diagnosis were included. Patients characteristics and disease parameters were recorded. PIV was calculated according to (neutrophil x platelet x monocyte/lymphocytei,.e. NxPxM/L) formula. Since a cut-o value with max sensitivity and speci city could not be obtained with ROC analysis, the median value of PIV was used as cut-o value. The relationship between PIV and pathological parameters was evaluated by ROC curves. The Kaplan-Meier method was used for OS and the log-rank test was used to evaluate the survival di erences between the two groups, according to the optimal cut-o point. Results: Based on the PIV cut-o value of 121 (49.8%) patients were in the low PIV and 122 (50.2%) patients were in the high PIV group. The patients in the high PIV group had a statistically signi cantly more advanced AJCC stage, and were younger patients. In the survival analysis, it was observed that the survival was worse in the high PIV group but this di erence did not reach statistical signi cance (p=0.112). Conclusion: Higher PIV levels at the time of diagnosis can be another prognostic marker. However, to clarify the PIV prognostic value, it needs to be validated in larger, multi-centre prospective clinical studies.
Publication Details
Page(s) 86-91
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Breast Cancer, prognosis, Pan immune-in ammation value (PIV), Young women
0

Citations

0

Downloads

143

Views